17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

Inclusion Criteria:

• Histologically confirmed solid tumor or lymphoma

  • Metastatic or unresectable disease
• Standard curative or palliative measures do not exist or are no longer effective
• No known brain metastases
• Performance status - ECOG 0-2
• Performance status - Karnofsky 60-100%
• More than 12 weeks
• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 9.0 g/dL
• ALT and AST ≤ 1.5 times upper limit of normal (ULN)
• Bilirubin ≤ normal
• Creatinine ≤ 1.25 times ULN
• Creatinine clearance ≥ 60 mL/min
• QTc < 450 msec for male patients (470 msec for female patients)
• LVEF > 40% by MUGA
• No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
• No myocardial infarction or active ischemic heart disease within the past year
• No New York Heart Association class III or IV congestive heart failure
• No poorly controlled angina
• No uncontrolled dysrhythmia requiring medication
• No left bundle branch block
• No history of congenital long QT syndrome
• No other significant cardiac disease
• Pulse oximetry at rest or on exercise > 88%

• No symptomatic pulmonary disease (e.g., chronic obstructive or restrictive pulmonary disease, etc.) or any of the following are allowed:

  • Pulmonary disease requiring medication
  • History of dyspnea, dyspnea on exertion, or paroxysmal nocturnal dyspnea
  • Patients meeting the Medicare criteria for home oxygen or are on oxygen
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective double barrier contraception 1 week before, during, and for at least 2 weeks after study participation
• No uncontrolled illness
• No active or ongoing infection
• No history of allergic reaction attributed to compounds of similar chemical or biological composition to 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG)
• No psychiatric illness or social situation that would preclude study compliance
• No concurrent routine colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF])
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Concurrent hormonal therapy allowed
• At least 4 weeks since prior radiotherapy and recovered
• No prior radiation that included the heart in the field (e.g., mantle)
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent anticancer agents or therapies
• No concurrent medication that would prolong the QTc interval
• No other concurrent investigational agents